Pazdur’s Post-Mortem On ‘Dangling’ Accelerated Approvals: Message At ODAC Was Heard Loud And Clear

The three-day advisory committee was intended to ‘put companies on notice’ about the importance of confirmatory trials. The result? Mission accomplished.

loudspeakers (Alamy)
• Source: Alamy

The immediate impact of the US Food & Drug Administration’s oncology advisory committee’s consideration of six “dangling” Accelerated Approvals in the PD-1 class – and the underlying message that FDA was getting serious about AA drugs that had failed confirmatory studies – was for a sponsor to volunteer to remove an indication from the market.

“I was shocked,” Oncology Center of Excellence and Director Rick Pazdur said during an 8 June interview with Prevision...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards